Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has alerted the market to four batches of medicines recalled by the Drug Regulatory Authority of Pakistan (DRAP) as adulterated or substandard, and says monitoring is under way to keep them out of Nigeria.
Importers, distributors, pharmacies and health facilities should check stock against the batch numbers below. NAFDAC has not said the products have been found in Nigeria; the alert is preventive, directed at entry and at anyone procuring from Pakistani suppliers. The glyceryl trinitrate finding warrants particular attention: it is used in acute angina, and a substandard batch means a patient may take a dose that does not work during a cardiac event.
| Product | Active ingredient | Batch | Manufacturer | DRAP finding |
|---|---|---|---|---|
| Nitras tablets | Glyceryl trinitrate | 24L069 | Caraway Pharma, Rawat | Substandard |
| Kadin 2 tablets | Tizanidine hydrochloride | 569 | FYNK Pharma, Lahore | Adulterated |
| Acefyl cough syrup | Acefylline piperazine | ACH479 | NABIQASIM Industries, Karachi | Adulterated |
| Loratadine 24 tablets | Loratadine | 24 | Murfy Pharma, Lahore | Adulterated |
NAFDAC said use of adulterated or substandard medicines may result in reduced efficacy, unexpected adverse reactions, treatment failure and serious health consequences, and that patients treated for cardiac conditions, allergies, muscle spasms and cough-related illness may face increased risk. All zonal directors and state coordinators have been instructed to conduct surveillance and remove the products if found. The agency advised buying only from authorised or licensed suppliers and checking product authenticity and condition.
Source: NAFDAC Public Alert No. 038/2026 — https://nafdac.gov.ng/public-alert-no-038-2026-alert-on-adulterated-and-substandard-medicines-nitras-kadin-2-acefyl-and-loratadine-24-recalled-by-the-drug-regulatory-authority-of-pakistan-drap/
